The Food and Drug Administration Dec. 17 issued a drug safety communication informing patients and health care professionals that the injection form of Anzemet (dolasetron mesylate) should no longer be used to prevent nausea and vomiting associated with cancer chemotherapy in pediatric and adult patients.
New data showed that Anzemet injection can increase the risk of developing an abnormal heart rhythm (torsade de pointes), which in some cases can be fatal, the agency said. Patients at particular risk are those with underlying heart conditions or those who have existing heart rate or rhythm problems. Anzemet is manufactured by Sanofi-aventis.
FDA ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.